Investor Overview

Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline and is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development.

Adverum Biotechnologies NASDAQ: ADVM
$3.7908/26/164:00 p.m. ET
+0.11 (+2.99%)

Data provided by Nasdaq.

Minimum 15 minutes delayed.

Recent News

View All

Upcoming Events

There are currently no events scheduled.
View All